L
Lixa develops NeoX™, a scalable technology designed to reverse bacterial resistance mechanisms, including biofilm formation. This platform restores the efficacy of existing antimicrobials against resistant bacteria across human health, agriculture, and industrial sectors. The company aims to provide cross-sector resistance breakers compatible with current antibiotics and biocides worldwide.
Updated 4 months ago
Funding
$1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Lixa develops the NeoX™ technology platform to restore the efficacy of existing antimicrobials against antibiotic-resistant bacteria and biofilm formations. This scalable solution addresses the global challenge of antimicrobial resistance (AMR) by enhancing the effectiveness of low-cost treatments in various environments and applications.